Axitinib (also known as AG-013736) is a small molecule tyrosine kinase inhibitor. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in xenograft models and renal cell carcinoma (RCC) and several other tumor types.